Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody
Citations Over TimeTop 10% of 2015 papers
Abstract
Microglia have been shown to contribute to the clearance of brain amyloid β peptides (Aβ), the major component of amyloid plaques, in Alzheimer's disease (AD). However, it is not known whether microglia play a similar role in the clearance of tau, the major component of neurofibrillary tangles (NFTs). We now report that murine microglia rapidly internalize and degrade hyperphosphorylated pathological tau isolated from AD brain tissue in a time-dependent manner in vitro. We further demonstrate that microglia readily degrade human tau species released from AD brain sections and eliminate NFTs from brain sections of P301S tauopathy mice. The anti-tau monoclonal antibody MC1 enhances microglia-mediated tau degradation in an Fc-dependent manner. Our data identify a potential role for microglia in the degradation and clearance of pathological tau species in brain and provide a mechanism explaining the potential therapeutic actions of passively administered anti-tau monoclonal antibodies.
Related Papers
- → AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy(2017)56 cited
- → NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model(2009)122 cited
- → Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies(2015)31 cited
- → Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem Brains(2022)15 cited
- → Bead‐based electrochemical gap sensors for detection of tau protein in blood to diagnosis and monitoring the tauopathy(2022)